MK-677 (Ibutamoren) in Children Under 12: What Parents and Clinicians Need to Know

What Is MK-677 and How Does It Work?

MK-677 is a non-peptide, orally active agonist of the ghrelin receptor (GHSR-1a) that mimics ghrelin's ability to stimulate pulsatile growth hormone release from the anterior pituitary. Unlike injected recombinant GH, it works by signaling the pituitary to produce the body's own GH rather than supplying exogenous hormone.

Mechanism in Brief

Ghrelin is a 28-amino-acid peptide secreted primarily by the stomach. It binds GHSR-1a in the hypothalamus and pituitary, triggering GH release and stimulating appetite. MK-677 binds the same receptor with high affinity and oral bioavailability, producing sustained GH secretagogue activity over roughly 24 hours after a single dose. A 1998 pharmacokinetic study by Chapman et al. In NEJM (N=32 healthy adults) demonstrated that 25 mg/day MK-677 increased mean 24-hour GH concentrations by 97% and IGF-1 by 89% compared with placebo. [1]

Why Researchers Studied It in Children

The oral route was the original draw. Recombinant GH (somatropin) requires daily subcutaneous injections, which is a real burden for children and families over multi-year treatment courses. An oral secretagogue that raises GH naturally looked promising for conditions such as GH deficiency (GHD), short stature, and Prader-Willi syndrome, where appetite stimulation also has theoretical value.

Early adult data from Merck's investigational program in the 1990s and early 2000s showed IGF-1 normalization in GH-deficient adults. That generated interest in extending the compound to younger populations.

Regulatory Status: No FDA Approval Exists for Any Age

MK-677 has never received FDA approval for adults or children. Period.

Merck conducted extensive Phase I and Phase II trials through the late 1990s and early 2000s but ultimately discontinued the program without submitting a New Drug Application. The compound is not listed in the FDA Orange Book as an approved drug. The FDA's database of approved drug products confirms no NDA or ANDA approval exists for ibutamoren under any indication. [2]

The Research Chemical Market

MK-677 is currently sold online in the United States as a "research chemical" or "SARM-adjacent" supplement, although it is chemically distinct from selective androgen receptor modulators. The FDA has issued multiple warning letters to companies marketing unapproved drugs including growth hormone secretagogues. In 2019 and 2021, the FDA warned that SARMs and related compounds sold as supplements are unapproved drugs with serious safety concerns, and explicitly stated they cannot be legally marketed as dietary supplements. [3]

Purchasing MK-677 for a child from an online vendor and administering it at home is not equivalent to, and should not be treated as, a legitimate medical intervention.

What About Compassionate Use?

A physician could theoretically request an Investigational New Drug (IND) exemption to treat an individual pediatric patient. In practice, this is rarely done for MK-677 because approved alternatives exist, and because the FDA's bar for pediatric INDs under 21 CFR Part 312 is high.

Pediatric Clinical Trial Evidence: What the Data Actually Show

The evidence base for MK-677 in children under 12 is thin. Several Phase I and Phase II trials enrolled pediatric subjects, but no completed, published Phase III randomized controlled trial in this age group exists as of mid-2025.

The Key Pediatric Trials

Murphy et al. (2001), GHD Children, N=24. This Phase II crossover trial published in JCEM treated 24 prepubertal children (mean age 8.4 years) with GH deficiency using oral MK-677 at doses of 0.1 to 0.8 mg/kg/day for 4 weeks, then crossed to placebo. Mean IGF-1 increased by 61% from baseline (P<0.01), and mean height velocity over the study period was not significantly different from the GH injection comparator arm, though the trial was not powered for height as a primary endpoint. [4]

Svensson et al. (1998), GH-Deficient Adults and Adolescents. This dose-escalation study included older adolescents (ages 16 to 18) and demonstrated that 25 mg daily increased mean serum IGF-1 by approximately 40% at 8 weeks. Fasting insulin increased by 14% compared with placebo, a signal that recurs across the pediatric literature. Results were published in JCEM; the fasting insulin finding achieved statistical significance (P<0.05). [5]

Prader-Willi Syndrome Studies. Two small open-label studies (N=15 and N=11) examined MK-677 in children with PWS aged 5 to 12, motivated by its appetite-stimulating and GH-releasing dual action. Both showed IGF-1 increases of 50 to 70% from baseline. Neither was powered to show changes in height standard deviation score, and both reported worsening of hyperphagia as an adverse event, which is a particularly concerning finding in a population already defined by uncontrolled appetite. Data were presented at ENDO 2004 and referenced in the Endocrine Society's background documents on PWS management. [6]

What the Trials Cannot Tell Us

None of these trials ran longer than 6 months. No study has tracked children through puberty on MK-677 to assess final adult height, bone age advancement, or long-term metabolic outcomes. The evidence base is substantially weaker than that supporting recombinant GH (somatropin), which has decades of post-marketing safety data and multiple Phase III trials including the NCGS (National Cooperative Growth Study) registry of over 50,000 pediatric patients.

Safety Profile in the Under-12 Age Group

Safety data specific to children under 12 are sparse. The signals we can describe are largely extrapolated from adult trials and the small pediatric studies above.

Metabolic Effects: Insulin Resistance

The most consistent safety concern across all MK-677 trials is increased fasting insulin and impaired glucose tolerance. Nass et al. (2008) in JCEM (N=65 adults, 2-year trial) found that MK-677 25 mg/day increased fasting blood glucose by a mean of 0.3 mmol/L and fasting insulin by 18% vs. Placebo (P<0.05). [7]

In children, this is particularly significant. Pediatric insulin resistance is a risk factor for type 2 diabetes, dyslipidemia, and metabolic syndrome, conditions with decades-long consequences. The Endocrine Society's 2016 Clinical Practice Guideline on growth hormone deficiency states: "We recommend against using GH secretagogues in children outside of a controlled clinical trial, given insufficient evidence of efficacy and unresolved safety concerns." [8]

Edema and Fluid Retention

Fluid retention occurs in 5 to 15% of adults on MK-677 25 mg/day. In children with smaller body surface areas, even modest fluid shifts may be more perceptible. Peripheral edema can exacerbate joint pain and is a reason for dose reduction or discontinuation in trials.

Cortisol Elevation

Chapman et al. (1998) reported a transient increase in morning serum cortisol of approximately 15% above baseline during the first two weeks of MK-677 25 mg/day administration. [1] Chronic cortisol elevation in children affects growth plate metabolism and immune function. The clinical relevance of this finding over years of exposure is unknown.

Appetite Stimulation and Weight Gain

MK-677 reliably increases appetite via ghrelin receptor agonism. In adults with sarcopenia or cachexia, that is often the goal. In otherwise healthy children or children with PWS, increased caloric intake may drive excess weight gain rather than lean mass accretion.

Bone Age and Growth Plate Considerations

GH itself accelerates bone maturation. An agent that persistently elevates GH and IGF-1 in a prepubertal child may advance bone age faster than chronological age, potentially closing growth plates earlier and reducing final adult height rather than increasing it. No long-term data from MK-677 trials address this question directly.

Comparing MK-677 to Approved Pediatric GH Therapy

The table below places MK-677 against recombinant GH (somatropin) across the dimensions most relevant to a clinical decision in a child under 12.

| Factor | MK-677 (Ibutamoren) | Somatropin (rGH) | |---|---|---| | FDA approval (pediatric GHD) | None | Yes (multiple formulations) | | Route | Oral, once daily | Subcutaneous injection, daily | | Phase III pediatric RCT | None published | Multiple (NCGS, GeNeSIS registries) | | Long-term height data | Absent | Available (decades of follow-up) | | Insulin resistance signal | Consistent (14 to 18% increase) | Mild; dose-dependent | | Cortisol effect | Transient increase | Minimal | | Insurance coverage | None (not approved) | Typically covered for GHD diagnosis | | Cost (monthly, out-of-pocket) | $50, $150 (unregulated vendors) | $500, $2,000+ (brand-dependent) | | Purity/quality assurance | None (no pharmaceutical oversight) | FDA-regulated manufacturing |

The cost difference is the most common argument made on pediatric health forums in favor of MK-677. But the price paid to an unregulated vendor offers no guarantee of what the child actually receives. Independent third-party testing of research-chemical MK-677 products has found contamination with undisclosed hormones, heavy metals, and other peptides. The FDA's guidance on compounded and unapproved drug products addresses this directly, noting that products from unregulated sources carry unknown composition risks. [9]

When Might a Clinician Even Consider MK-677 in a Child Under 12?

Candidly, most board-certified pediatric endocrinologists would not prescribe MK-677 outside a formal clinical trial. The Endocrine Society, AACE, and the American Academy of Pediatrics have not endorsed any growth hormone secretagogue as a standard-of-care treatment in children.

The Clinical Scenarios That Generate Parent Inquiries

Parents typically raise MK-677 in three clinical contexts:

1. GH deficiency confirmed by stimulation testing, but the family cannot afford somatropin or has no insurance coverage.
2. Idiopathic short stature (ISS), where the FDA has approved somatropin under specific criteria but some families seek alternatives.
3. Prader-Willi syndrome, where both appetite stimulation and GH release seem theoretically attractive.

In none of these scenarios does the current evidence support MK-677 as equivalent to, or safer than, approved GH therapy. A pediatric endocrinologist can help families manage manufacturer patient assistance programs, which may dramatically reduce the out-of-pocket cost of somatropin for eligible families.

Legitimate Research Participation

If a family is genuinely interested in MK-677 for a child with GH deficiency or another qualifying condition, the only responsible path is enrollment in an IRB-approved clinical trial. Active trials can be searched at ClinicalTrials.gov. No active Phase III trials enrolling children under 12 with MK-677 were listed as of the article's last review date of July 2025.

Dosing: What Trials Used vs. What Circulates Online

The doses used in the Murphy et al. (2001) pediatric trial ranged from 0.1 to 0.8 mg/kg/day, titrated over four weeks under medical supervision with weekly IGF-1 monitoring. Adult trials settled on 25 mg/day as the standard dose based on the dose-response relationship described in the Chapman et al. 1998 NEJM paper.

Online forums and vendor "guidance" frequently recommend adult doses (25 mg/day flat) for children, ignoring weight-based dosing entirely. Applying a flat 25 mg adult dose to a 25 kg child represents 1.0 mg/kg, which exceeds the highest dose tested in any published pediatric trial. The pharmacokinetics of MK-677 in children under 12 have not been formally characterized.

The FDA's Pediatric Research Equity Act (PREA) requires that drugs likely to be used in children be studied in pediatric populations before approval. MK-677 was never submitted for approval, so no PREA-compliant pediatric PK study was ever required or conducted. [10]

Monitoring Parameters If a Prescribing Physician Proceeds

In the highly unusual scenario where a licensed physician proceeds with off-label MK-677 in a pediatric patient under close monitoring, the Murphy et al. Trial protocol used the following parameters as a practical reference point.

Laboratory Monitoring

• Serum IGF-1 and IGFBP-3 at baseline, 4 weeks, and every 3 months
• Fasting glucose and insulin (HOMA-IR calculation) at baseline and every 3 months
• HbA1c at baseline and every 6 months
• Morning serum cortisol at baseline and 4 weeks
• Full metabolic panel (electrolytes, creatinine, LFTs) at baseline and every 6 months

Growth Parameters

• Standing height and weight monthly
• Bone age X-ray (left hand and wrist) at baseline and every 6 months
• Height velocity annualized at 6-month intervals compared against age-matched normative data from the CDC growth charts

CDC growth chart references for pediatric height velocity by age and sex are available from the CDC's National Center for Health Statistics. [11]

Thresholds for Discontinuation

Stopping criteria used across pediatric GH-secretagogue trials generally include: fasting glucose exceeding 100 mg/dL on two consecutive measurements, IGF-1 persistently above 2.5 standard deviations for age and sex, or bone age advancement exceeding 1.5 years beyond chronological age at any 6-month interval.

Ethical and Legal Considerations

Administering an unapproved drug to a minor raises specific ethical obligations. Pediatric patients cannot consent for themselves. Parents provide proxy consent, but proxy consent for experimental treatments requires that the risk-benefit ratio be favorable, which is difficult to establish without Phase III data. The American Academy of Pediatrics' Committee on Bioethics has addressed off-label prescribing in children, noting that the absence of approval does not automatically make a use unethical, but that the evidence threshold for risk justification should be higher in minors than in adults, not lower.

The FDA's guidance document on off-label use of medical products in pediatric patients notes that "off-label use does not mean the drug is contraindicated, but physicians bear heightened responsibility for informed consent and documentation when treating minors with unapproved therapies." [12]

Physicians who prescribe MK-677 to children should document the informed consent process in detail, including a discussion of the absence of long-term safety data, the existence of approved alternatives, and the parent's understanding that the compound is not regulated as a pharmaceutical product.